Genmab A (GMAB) Cash from Financing Activities (2018 - 2026)
Genmab A (GMAB) posted Cash from Financing Activities of -$177.0 million for Q1 2026, up 59.77% on a QoQ basis from -$440.0 million in Q3 2025, and down 1261.54% year-over-year from $15.2 million in Q1 2025.
Genmab A (GMAB) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Genmab A's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$177.0 million for Q1 2026.
- Quarterly Cash from Financing Activities fell 1261.54% year-over-year to -$177.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (up 37.11% YoY) and the FY2025 annual result came in at $4.8 billion, up 946.11% from the prior year.
- Cash from Financing Activities was -$177.0 million for Q1 2026 at Genmab A, up from -$440.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$13.0 million in Q1 2025 and bottomed at -$566.0 million in Q4 2024.
- A 4-year average of -$319.8 million and a median of -$419.0 million in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities jumped 84.71% — and 2026, when it sank 1261.54%.
- Genmab A's Cash from Financing Activities stood at -$89.0 million in 2023, then sank by 535.96% to -$566.0 million in 2024, then grew by 22.26% to -$440.0 million in 2025, then jumped by 59.77% to -$177.0 million in 2026.
- Business Quant data shows GMAB's Cash from Financing Activities at -$177.0 million in Q1 2026, -$440.0 million in Q3 2025, and -$419.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | -177.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.00 Mn |
| Mar 31, 2026 | -177.00 Mn |
| Sep 30, 2025 | -440.00 Mn |
| Sep 30, 2025 | -440.00 Mn |
| Jun 30, 2025 | -419.00 Mn |
| Jun 30, 2025 | -419.00 Mn |
| Mar 31, 2025 | -13.00 Mn |
| Mar 31, 2025 | -13.00 Mn |
| Dec 31, 2024 | -566.00 Mn |
| Dec 31, 2024 | -566.00 Mn |
| Sep 30, 2024 | -564.00 Mn |
| Sep 30, 2024 | -564.00 Mn |
| Jun 30, 2024 | -525.00 Mn |
| Jun 30, 2024 | -525.00 Mn |
| Mar 31, 2024 | -85.00 Mn |
| Mar 31, 2024 | -85.00 Mn |
| Dec 31, 2023 | -89.00 Mn |
| Dec 31, 2023 | -89.00 Mn |
| Sep 30, 2020 | 19.00 |
| Sep 30, 2020 | 19.00 |